Quest Diagnostics Incorporated (DGX) — Fair Value Analysis

Base-case fair value (P50): $237.93 · Current price: $234.40 · Verdict: Fairly Valued

The Verdict on DGX

Quest Diagnostics (DGX) is currently deemed Fairly Valued by our comprehensive Monte Carlo simulations. Trading at $234.40, DGX aligns closely with its median fair value (P50) of $237.93, a figure derived from thousands of forward-looking financial scenarios. This outcome suggests that the market's current assessment largely incorporates the intrinsic value revealed by our probabilistic models. With only +1.5% against the current price, the valuation picture indicates that immediate significant appreciation due to a re-rating is unlikely. Instead, DGX's valuation at $234.40 implies that current fundamentals and future prospects are already priced in, offering limited immediate upside from a valuation discrepancy perspective.

How DGX stacks up against Healthcare

Within the competitive Healthcare sector, DGX maintains a strong quality tier, reflecting its robust operational and financial health. This fundamental strength is a key input into our Monte Carlo simulations and underpins the Fairly Valued verdict. While DGX's quality metrics are demonstrably strong, the simulation's results suggest that the market has efficiently capitalized on these attributes at $234.40. Unlike companies with similar strong fundamentals that might trade at a discount, DGX's valuation relative to its $237.93 indicates that its sector-leading position is fully recognized. The slim +1.5% further corroborates this market efficiency in pricing DGX's inherent quality.

What this means for investors

For investors considering DGX, the Fairly Valued assessment, with $234.40 closely mirroring $237.93 and a modest +1.5%, suggests that future returns will predominantly stem from organic business growth and broader Healthcare sector dynamics, rather than a significant re-rating to a higher fair value. While the strong quality tier provides a robust foundation for long-term stability and resilience, it doesn't currently signal an undervalued opportunity based on our Monte Carlo analysis. Our FairCurve platform offers a deeper dive into these simulations. To see the full bear/bull distribution and track DGX's fair value as new fundamentals are released, sign up for a free FairCurve account today.